CLSN Key Statistics, Chart & Performance
The current stock price of CLSN is 1.96 USD. In the past month the price decreased by -15.52%. In the past year, price decreased by -87.06%.
CLSN Technical Analysis
CLSN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSN. CLSN may be in some trouble as it scores bad on both profitability and health.
CLSN Financial Highlights
Over the last trailing twelve months CLSN reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS decreased by -35.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5229.82% | ||
| ROA | -40.03% | ||
| ROE | N/A | ||
| Debt/Equity | 0.13 |
CLSN Forecast & Estimates
8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96.
CLSN Ownership
CLSN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.08 | 387.092B | ||
| AMGN | AMGEN INC | 16.32 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 16.72 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.25 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 12 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLSN
Company Profile
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Company Info
CELSION CORP
997 Lenox Dr Ste 100
Lawrence Township NEW JERSEY 08648 US
CEO: Michael H. Tardugno
Employees: 29
Phone: 16098969100.0
CELSION CORP / CLSN FAQ
What does CLSN do?
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Can you provide the latest stock price for CELSION CORP?
The current stock price of CLSN is 1.96 USD.
Does CLSN stock pay dividends?
CLSN does not pay a dividend.
How is the ChartMill rating for CELSION CORP?
CLSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
When does CELSION CORP (CLSN) report earnings?
CELSION CORP (CLSN) will report earnings on 2022-11-14.
Can you provide the ownership details for CLSN stock?
You can find the ownership structure of CELSION CORP (CLSN) on the Ownership tab.